Lisofylline

利索茶碱

Report date: 2022/03/01 13:29:02

Base Information

Drug NameLisofylline
Drug Alias NameLSFProTecBL-194CT-1501RA-802710
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-12 inhibitorsLysophosphatidic acid acyltransferase inhibitorsSignal transducer and activator of transcription 4 inhibitors
TargetsInterleukin-12Lysophosphatidic acid acyltransferaseSignal transducer and activator of transcription 4
Therapy Area/IndicationsRejection of organ transplantationDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCti Biopharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesCti Biopharma CorpIslet Sciences
Inactive CompaniesEastern Virginia Medical SchoolDiakine Therapeutics Inc
Active IndicationsRejection of organ transplantation
Inactive IndicationsDiabetes Mellitus, Type 1

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG